Events
News
05/2020 GENSPEED is funded by Austrian Research Promotion Agency for development of unique COVID19 rapid test
GENSPEED develops first point of care test that allows to target both, infected and recovered patients.
GENSPEED develops first point of care test that allows to target both, infected and recovered patients.
05/2020 Upper Austrian Hightechfonds invests in GENSPEED Biotech
With the recent investment in GENSPEED Biotech GmbH, the Upper Austrian Hightechfonds has brought a promising biotech company into its portfolio. GENSPEED is currently starting with the development of a rapid test for COVID-19 from…
06/2020 COVID19 Antibodytest by End of July
The 1. test in the COVID19 testportfolio based on the GENSPEEDs µELISA platform is an antibody test and gives lab-quality results in a finger prick drop of blood within 15 minutes at the point of need. Since the test detects specific antibodies against three SARS-Cov 2 antigens and also identifies antibodies against other human Corona Virustypes (e.g. OC43) it will be both highly specific and sensitive. The new test will be available by the end of July. Antigentest and world’s first combined Antibody / Antigentest will follow!
